When the cytokine is released, binds to CD122 (IL-2 receptor beta subunit) and the mAb may act synergistically with NKTR-214 by blocking PD-1 activation through the mAb and simultaneously stimulating growth and cytotoxic activity against the tumor of the patient’s T and NK cells by the exogenous IL-2. Here, IL2RB is linked to neoplasm.